论文信息 - Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer - 字舞流文

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

F. Holmes | J. O’Shaughnessy | J. Pippen | Stephen E. Jones | J. Blum | F. Gilberg | S. Vukelja | R. Rivera | S. Sedlacek | D. Paul | K. McIntyre | C. Stokoe | C. Brownstein | R. Pluenneke | J. Schwartz | R. Brooks | L. Krekow | D. Lindquist